These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 23066824)

  • 1. Amorphous solid dispersion successfully improved oral exposure of ADX71943 in support of toxicology studies.
    Ayad MH; Bonnet B; Quinton J; Leigh M; Poli SM
    Drug Dev Ind Pharm; 2013 Sep; 39(9):1300-5. PubMed ID: 23066824
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of three different types of cilostazol-loaded solid dispersion: Physicochemical characterization and pharmacokinetics in rats.
    Mustapha O; Kim KS; Shafique S; Kim DS; Jin SG; Seo YG; Youn YS; Oh KT; Yong CS; Kim JO; Choi HG
    Colloids Surf B Biointerfaces; 2017 Jun; 154():89-95. PubMed ID: 28324691
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved dissolution behavior of lipophilic drugs by solid dispersions: the production process as starting point for formulation considerations.
    Srinarong P; de Waard H; Frijlink HW; Hinrichs WL
    Expert Opin Drug Deliv; 2011 Sep; 8(9):1121-40. PubMed ID: 21722000
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of hot melt co-formulated antimalarial solid dispersion system in fixed dose form (ARLUMELT): Evaluating amorphous state and in vivo performance.
    Fule R; Dhamecha D; Maniruzzaman M; Khale A; Amin P
    Int J Pharm; 2015 Dec; 496(1):137-56. PubMed ID: 26471056
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Melt dispersion granules: formulation and evaluation to improve oral delivery of poorly soluble drugs - a case study with valsartan.
    Chella N; Tadikonda R
    Drug Dev Ind Pharm; 2015 Jun; 41(6):888-97. PubMed ID: 24796274
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Physicochemical characterization and in vivo evaluation of flurbiprofen-loaded solid dispersion without crystalline change.
    Oh DH; Park YJ; Kang JH; Yong CS; Choi HG
    Drug Deliv; 2011 Jan; 18(1):46-53. PubMed ID: 20726805
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of solid carriers on the crystalline properties, dissolution and bioavailability of flurbiprofen in solid self-nanoemulsifying drug delivery system (solid SNEDDS).
    Kang JH; Oh DH; Oh YK; Yong CS; Choi HG
    Eur J Pharm Biopharm; 2012 Feb; 80(2):289-97. PubMed ID: 22119666
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of exposure properties after injection of nanosuspensions and microsuspenions into the intraperitoneal space in rats.
    Sigfridsson K; Lundqvist A; Strimfors M
    Drug Dev Ind Pharm; 2013 Nov; 39(11):1832-9. PubMed ID: 23240709
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced dissolution and bioavailability of biochanin A via the preparation of solid dispersion: in vitro and in vivo evaluation.
    Han HK; Lee BJ; Lee HK
    Int J Pharm; 2011 Aug; 415(1-2):89-94. PubMed ID: 21645596
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preparation, characterization and in vivo studies of amorphous solid dispersion of berberine with hydrogenated phosphatidylcholine.
    Shi C; Tong Q; Fang J; Wang C; Wu J; Wang W
    Eur J Pharm Sci; 2015 Jul; 74():11-7. PubMed ID: 25861719
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved dissolution and pharmacokinetic behavior of cyclosporine A using high-energy amorphous solid dispersion approach.
    Onoue S; Sato H; Ogawa K; Kawabata Y; Mizumoto T; Yuminoki K; Hashimoto N; Yamada S
    Int J Pharm; 2010 Oct; 399(1-2):94-101. PubMed ID: 20705124
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel valsartan-loaded solid dispersion with enhanced bioavailability and no crystalline changes.
    Yan YD; Sung JH; Kim KK; Kim DW; Kim JO; Lee BJ; Yong CS; Choi HG
    Int J Pharm; 2012 Jan; 422(1-2):202-10. PubMed ID: 22085435
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of novel itraconazole-loaded solid dispersion without crystalline change with improved bioavailability.
    Park YJ; Xuan JJ; Oh DH; Balakrishnan P; Yang HJ; Yeo WH; Lee MK; Choi HG; Yong CS
    Arch Pharm Res; 2010 Aug; 33(8):1217-25. PubMed ID: 20803125
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of raloxifene-solid dispersion with improved oral bioavailability via spray-drying technique.
    Tran TH; Poudel BK; Marasini N; Woo JS; Choi HG; Yong CS; Kim JO
    Arch Pharm Res; 2013 Jan; 36(1):86-93. PubMed ID: 23325488
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preparation of an amorphous sodium furosemide salt improves solubility and dissolution rate and leads to a faster Tmax after oral dosing to rats.
    Nielsen LH; Gordon S; Holm R; Selen A; Rades T; Müllertz A
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):942-51. PubMed ID: 24075980
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of the solid-dispersion method on the solubility and crystalline property of tacrolimus.
    Joe JH; Lee WM; Park YJ; Joe KH; Oh DH; Seo YG; Woo JS; Yong CS; Choi HG
    Int J Pharm; 2010 Aug; 395(1-2):161-6. PubMed ID: 20580799
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cefuroxime axetil solid dispersion with polyglycolized glycerides for improved stability and bioavailability.
    Dhumal RS; Biradar SV; Aher S; Paradkar AR
    J Pharm Pharmacol; 2009 Jun; 61(6):743-51. PubMed ID: 19505364
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Formulation of solid dispersion of rebamipide evaluated in a rat model for improved bioavailability and efficacy.
    Tung NT; Park CW; Oh TO; Kim JY; Ha JM; Rhee YS; Park ES
    J Pharm Pharmacol; 2011 Dec; 63(12):1539-47. PubMed ID: 22060284
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Solid dispersion technology as a strategy to improve the bioavailability of poorly soluble drugs.
    Cid AG; Simonazzi A; Palma SD; Bermúdez JM
    Ther Deliv; 2019 Jun; 10(6):363-382. PubMed ID: 31094298
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In silico prediction of the solubility advantage for amorphous drugs - Are there property-based rules for drug discovery and early pharmaceutical development?
    Kuentz M; Imanidis G
    Eur J Pharm Sci; 2013 Feb; 48(3):554-62. PubMed ID: 23262058
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.